https://www.selleckchem.com/pr....oducts/FK-506-(Tacro
iol, ALP, and blood CD3, CD4 and CD8 counts were not significantly difference between two treatments ( 0.05). Serious side effects or reactions were not reported in all included studies. The adjunctive use of CM reduced the endocrine therapy associated adverse events, including bone mineral density loss, perimenopausal symptoms, poor quality of life, pain and impaired immune function. But large-scale and high quality RCTs are needed to support the application of CM-WM therapy. The adjunctive use of CM reduced the endocrine t
Like
Comment
Share
